Purpose Regular surveillance decreases the risk of recurrent cancer in colorectal cancer (CRC) survivors. However, studies suggest that receipt of follow-up tests is not consistent with guidelines. This systematic review aimed to: (1) examine receipt of recommended post-treatment surveillance tests and procedures among CRC survivors, including adherence to established guidelines, and (2) identify correlates of CRC surveillance. Methods Systematic searches of Medline, PubMed, PsycINFO, CINAHL Plus, and Scopus databases were conducted using terms adapted for each database's keywords and subject headings. Studies were screened for inclusion using a three-step process: (1) lead author reviewed abstracts of all eligible studies; (2) coauthors reviewed random 5 % samples of abstracts; and (3) two sets of coauthors reviewed all "maybe" abstracts. Discrepancies were adjudicated through discussion. Results Thirty-four studies are included in the review. Overall adherence ranged from 12 to 87 %. Within the initial 12 to 18 months post-treatment, adherence to recommended office visits was 93 %. Adherence ranged from 78 to 98 % for physical exams, 18-61 % for colonoscopy, and 17-71 % for carcinoembryonic antigen (CEA) testing. By 2 to 3 years posttreatment, cumulative adherence ranged from 70 to 88 % for office visits, 89-93 % for physical exams, 49-94 % for colonoscopy, and 7-79 % for CEA testing. Between 18 and 28 % of CRC survivors received greater than recommended overall surveillance; overuse of physical exams (42 %), colonoscopy (24-76 %), and metastatic disease testing (1-29 %) was also prevalent. Studies of correlates of CRC surveillance focused on sociodemographic and disease/treatment characteristics, and patterns of association were inconsistent across studies. Conclusions Deviation from surveillance recommendations includes both under-and overuse. Examination of modifiable determinants is needed to inform interventions targeting appropriate and timely receipt of recommended surveillance. Implications for Cancer Survivors Among CRC survivors, it remains unclear what modifiable psychosocial factors are associated with the observed under-and overuse of surveillance. Understanding and intervening with these psychosocial factors is critical to improving adherence to guidelinerecommended surveillance and thereby reducing mortality among this group of survivors.
Introduction
Colorectal cancer (CRC) is the third most common cancer among both men and women in the USA [1] . Although a majority (about two thirds) of CRC patients present with local or regional disease for which tumor resection with curative intent is the treatment of choice [2] , 28 to 50 % of patients will develop recurrent disease [3] [4] [5] [6] [7] . Because CRC survivors are at high risk for recurrence, the goals of post-treatment surveillance are to detect early stage recurrences that are amenable to another curative resection or to detect polyps and precancerous lesions at a pre-invasive stage, thereby reducing mortality [2, 8] .
Clinical practice guidelines from various oncological, surgical, and gastroenterological organizations recommend routine post-treatment surveillance of CRC survivors [9] [10] [11] [12] [13] . Although the frequency of and interval between surveillance tests and procedures have been debated and modified in recent years, the majority of current guidelines recommend regular provider office visits [9, 12, 13] , colonoscopy at 1 year post-resection with follow-up colonoscopy every 3-5 years [10, 11, 13] , and carcinoembryonic antigen (CEA) testing for the first 2-5 years post-resection [9, 12, 13] . There is less consistency regarding recommendations for metastatic disease testing (e.g., x-ray, CT scan, ultrasound), and some organizations have modified their guidelines in recent years to recommend previously nonrecommended procedures (i.e., CT scans) [9] [10] [11] [12] [13] . Results from several systematic reviews and meta-analyses demonstrate a modest but statistically significant survival benefit from more intense versus minimal surveillance (defined as any versus no follow-up to varying combinations of and intervals for followup tests and procedures) [14] , including earlier detection of asymptomatic and local recurrences [6, 7] , successful reoperation rates [6] , and a 4 to 33 % decrease in overall mortality [5, 6, 14] .
Regardless of the CRC surveillance guidelines used, receipt of CRC follow-up tests and procedures is quite variable [2, . Moreover, relatively little is known about correlates of CRC surveillance, with the available evidence focused on patient-level sociodemographic, disease, and treatment factors [2, 15-18, 21-28, 30, 31, 33, 34, 37, 38, 40-43, 45-47] , as opposed to psychosocial, provider-and/or system factors that may help inform the development of interventions to promote surveillance.
The documented variability in receipt of surveillance among CRC survivors despite evidence for its effectiveness highlights the need for a systematic review of this topic in order to establish the magnitude of the problem and to identify factors that can be targeted in interventions to increase CRC surveillance. Previous reviews of surveillance follow-up care which included CRC survivors were either too broad (i.e., examined factors related to health service utilization among survivors of a number of cancer sites) [48] or too specific in focus (i.e., ethnic disparities in colonoscopy use) [49] . Accordingly, the specific aims of this systematic review were to: (1) examine receipt of recommended post-treatment surveillance tests and procedures (i.e., office visits, physical exams, colonoscopy, CEA testing, metastatic disease testing) among CRC survivors, including adherence to established guidelines when possible, and (2) identify correlates of CRC surveillance. We also assessed completeness of reporting on selected characteristics relevant to internal and external validity based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist [50] .
Methods

Search strategy
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used to guide the content and reporting of this systematic review [51] . Using various interfaces, electronic searches of four databases were conducted: Medline (via Ovid; 1946 January 23, 2013) . General concepts that comprised the search included: c o l o r e c t a l c a n c e r, s u r v i v o r s , f o l l o w -u p , a n d surveillance/screening methods. Although the term "surveillance" is the one most often used when referring to screening tests in persons with a previous diagnosis of cancer, there is not absolute consistency; therefore, both "surveillance" and "screening" were utilized as search terms. All search terms were adapted for each database's unique keywords and subject headings with the assistance of a health sciences librarian experienced in developing systematic review search strategies. Strategies were pretested and refined through an iterative process which involved screening citations for relevance to our eligibility criteria. The final strategies for each database searched are presented in the Appendix. In addition to the documented search strategies, reference lists from eligible articles were hand searched for additional studies. Relevant articles were also searched in Scopus (via Elsevier) to determine whether they had been cited by other studies that previous searches had not found. Figure 1 illustrates the flow of information through the different phases of the systematic review.
Inclusion and exclusion criteria
Studies were considered eligible if they: (1) were written in English; (2) were published or in press in a peerreviewed journal; (3) reported data from a primary study (i.e., not a review, editorial, or commentary); (4) included CRC survivors; and (5) reported data on the prevalence and/or correlates of CRC surveillance tests and procedures (i.e., office visits, physical exams, colonoscopy, CEA testing, metastatic disease testing). Inclusion criteria were assessed in the order specified above; the first "no" criterion was the documented reason for exclusion and the remaining criteria were not assessed. According to the Cochrane group, a single failed criterion is sufficient cause to exclude a study from the review [52] . As this represents the first comprehensive systematic review of the topic, no exclusions were made on the basis of year of publication. Studies which did not clearly specify that physician/office visits were for the purpose of surveillance were excluded from this review as were studies that examined prevalence of adherence to CRC surveillance guidelines in clinical trial populations.
Selection of studies
Studies were screened using a three-step process. First, the titles and abstracts of all potentially eligible studies were screened by the lead author who assigned a rating of "no" or "maybe" as to whether each study should be included in the review. Next, each coauthor independently reviewed a random 5 % sample of abstracts. The random 20 % sample of abstracts double-screened for inclusion was considered an adequate representation of eligible abstracts (similar to double-coding or double-checking in original research). Discrepancies in ratings across co-authors occurred in <5 % of all abstracts reviewed; all discrepancies were adjudicated through discussion until consensus was reached. Finally, the titles and abstracts of all studies rated "maybe" over the first two screening steps were reviewed by two pairs of co-authors. This process was conducted to ascertain final agreement regarding studies whose full text should be reviewed for potential inclusion. Both pairs of authors were in 100 % agreement as to the appropriateness of all "maybe" studies for subsequent full-text review.
Data extraction
Using an abstraction form created for this review, relevant information was extracted from all eligible studies. To assess aim 1, data on receipt of recommended post-treatment surveillance tests and procedures, including authors' operational definitions of adherence (i.e., type and frequency of surveillance tests and procedures) and the basis for their adherence # of full-text articles excluded, with reasons n = 27 Not a primary study, n = 4 Not specific to CRC survivors, n = 13 Not focused on prevalence and/or correlates of CRC surveillance, n = 9 Not specific to CRC survivors in community settings, n = 1 # of duplicate citations excluded n = 438 Fig. 1 Selection of studies for systematic review definition (i.e., recommending organization and year of recommendation), were extracted. Adherence to surveillance was judged according to the particular guideline(s) mentioned in the individual studies. To assess aim 2, data on correlates of CRC surveillance were extracted. Data were also abstracted on relevant study characteristics such as study design, data sources, sample size, subject eligibility criteria, and study follow-up period. All eligible studies were independently read and coded by two reviewers using the abstraction form. Discrepancies in coding occurred in <5 % of all studies; all discrepancies were adjudicated through discussion until consensus was reached between the two coders.
Completeness of reporting on selected characteristics of internal and external validity
Using the STROBE checklist [50] , studies were assessed for completeness of reporting on 20 selected aspects of internal and external validity related to the study population, design and analysis, and generalizability. Each characteristic was assigned a rating of "yes, explicitly reported by study authors"; "inferred by raters but not explicitly reported by study authors"; or "no, not reported by study authors." To assess the study population, ratings were assigned as to whether the authors reported setting/location of the study, data collection dates, participant eligibility criteria, source of participants, method of selection into the study, number of potentially eligible participants, number of participants included in the study, number of participants with complete follow-up, and number of analyzed participants.
To assess design and analysis characteristics, ratings were assigned as to whether the authors defined their outcome variables; identified sources of data and methods of assessment; provided information on how study sample size was determined; reported descriptive information regarding participant characteristics, potential confounders, and length of follow-up; and reported unadjusted and/or adjusted estimates. To assess generalizability, ratings were assigned as to whether authors discussed study limitations, including potential bias, as well as issues of external validity.
Results
Database searches, hand searching of reference lists, and citation tracking yielded 548 unique articles. After title/abstract review, 61 articles remained eligible for full-text review and, of these, 34 met criteria for inclusion ( 
Prevalence of adherence
Office visits During the initial 12 to 18 months post-surgery, 93 % of CRC survivors adhered to recommended office visits [2] . At 2 to 3 years post-treatment, 70-88 % of survivors adhered to office visits [2, 18, 19] , and at 3.5 years posttreatment, 92 % adhered [24] . Data reported by Cheung et al. [20] indicated that 23 % of both academic and communitybased Canadian CRC survivors received less than the recommended number of 8-14 office visits over a 5-year period of surveillance, whereas 17 % of survivors from an academic cancer center (and none from a community cancer center) received more than the recommended number. Median number of office visits over 5 years among academic and community-based survivors was 11 and 9, respectively. In the sole cross-sectional survey, Haggstrom et al. [30] found that 27 % of U.S. CRC survivors reported one office visit, 34 % reported two office visits, and 39 % reported three or more office visits in the past 12 months. Using SEERMedicare data in tandem with the American Medical Association Masterfile and the Unique Physician Identification Number Registry, Pollack et al. [35] found that 26 % of long-term CRC survivors had physician visits with hematologists/oncologists, while 73 % had visits with a primary care provider during the 6th to 12th year since diagnosis.
Physical/clinical exams Approximately 78-98 % of CRC survivors adhered to recommended physical/clinical exams during the initial 12 to 18 months post-surgery [27, 29, 40] and 89-93 % adhered within 2 to 3 years post-diagnosis and treatment [29] . Data reported by Boulin et al. [17] indicated that 35 % of CRC survivors in France fell below and 42 % fell above the recommendations for physical/clinical exams. [33] reported that 48 % of CRC survivors received colonoscopy 1-4 years post-diagnosis, 40 % received colonoscopy 4-7 years post-diagnosis, and 31 % received colonoscopy 7+years post-diagnosis. Mean number of colonoscopies over approximately 3-year periods of surveillance among U.S. Medicare beneficiaries ranged from 1.4 to 2.8 [21, 39] . Likewise, mean colonoscopies over a 5-year period of surveillance in France were 2 and 5 in minimal and standard follow-up groups, respectively [16] . Median number of colonoscopies among Canadian CRC survivors from both academic and community cancer centers was 2 over the course of 5 years [20] . In this study, Cheung et al. [20] found that 15 % of academic and 3 % of community-based survivors received less than whereas 67 % of survivors from an academic cancer center and 76 % of survivors from a community cancer center received more than the recommended single colonoscopy over the 5-year period of surveillance. Similar results were obtained in a French study where Boulin et al. [17] reported that 20 % of CRC survivors fell below and 24 % were above the recommendations for colonoscopy.
Several studies examined early receipt of colonoscopy after colonoscopy with normal results and found that 17-62 % of CRC survivors received a second colonoscopy within 18 months of initial colonoscopy [27, 38, 40, 42] and 27 % of survivors received a third colonoscopy within 2 years of a second normal colonoscopy [42] . These results were comparable to those obtained in a French sample where 29 % of CRC survivors received colonoscopy at a period inconsistent with recommended guidelines [17] .
CEA testing During the initial 12 to 18 months post-surgery, 17-71 % adhered to CEA testing [2, [26] [27] [28] [29] . Adherence to CEA testing ranged from 7 to 79 % within 2 to 3.5 years post-diagnosis and treatment [2, 17-19, 21, 24, 26, 29, 34, 44] and 87 % at 5-years post-diagnosis and treatment [26] . Adherence to surveillance was judged according to the particular guideline(s) mentioned in the individual studies. Individual studies' definitions of adherence varied. The majority of studies explicitly stated that they based their definition of adherence on a specific guideline(s) (n=12), yet other studies only referenced published guidelines (n=12). A few studies did not provide any basis for the definitions of adherence (n=7). CRC colorectal cancer, admin administrative, comm community, pop population, post-dx, post-diagnosis, post-tx post-treatment, NR not reported, OV office visits, PE physical examination, CE colon examination (i.e., colonoscopy, sigmoidoscopy, and/or barium enema; majority of exams, 77-99 %, were colonoscopy), COL colonoscopy, SIG sigmoidoscopy, BE barium enema, CEA carcinoembryonic antigen test, CBC complete blood counts, CT computed tomography, CXR chest x-rays, LFT liver function tests, US ultrasound, OMD other metastatic disease testing (e.g., x-ray, Approximately 41 % of Canadian CRC survivors from academic cancer centers and 29 % of survivors from community cancer centers received less than the recommended 8-30 CEA tests over a 5-year period of surveillance, with a median number of 9 CEA tests over 5 years among survivors in both settings [20] . In France, mean number of CEA tests were 3 and 12 in minimal and standard follow-up groups, respectively [16] . Within a 3-year surveillance period of U.S. Medicare beneficiaries, the mean number of CEA tests was 2.3 [21] .
Metastatic disease testing Fewer studies examined adherence to metastatic disease testing among CRC survivors, perhaps an artifact of inconsistent guidelines in this area. In France, Boulin et al. [17] found that 65 % of CRC survivors fell below French 1998 consensus guidelines which recommended abdominal ultrasound every 3-6 months for the first 3 years; 52 % of survivors fell below recommended guidelines for chest x-ray annually for 5 years. Smaller proportions of survivors were over these recommended standards for abdominal ultrasound and chest x-ray, 1 and 29 %, respectively. Mean number of ultrasounds over a 5-year period of surveillance were 2 and 6 in minimal and standard follow-up groups of French CRC survivors, respectively, whereas mean number of chest x-rays were 1 and 4 in minimal and standard follow-up groups, respectively [16] .
Among studies guided by U.S. professional organizations (ASCO, NCCN) prior to their recommendation of CT imaging, receipt of non-recommended testing ranged from 42 % (chest CT) to 94 % (complete blood count) among Canadian CRC survivors from an academic cancer center and 37 % (chest CT) to 100 % (liver function tests) among survivors from a community cancer center [20] . Receipt of imaging among U.S. military personnel and families ranged from 24 % (PET scans) to 78 % (CT scans) over 3 years [29] . Since the introduction of CT imaging recommendations into ASCO guidelines in 2005, the prevalence of liver imaging using CT, ultrasound, or MRI among Canadian survivors was 47 % in each yearly interval of a 3-year surveillance period [43] . Similar rates of metastatic disease testing, ranging from 15 % for abdominal ultrasound to 74 % for liver enzymes, were observed among both Canadian and U.S. populations [19, 21] ; however, no specific guidelines were cited or identified as the basis for adherence.
Overall surveillance Although the specific surveillance recommendations and timing of such recommendations varied by study, a number of studies examined the proportion of CRC survivors who received all recommended surveillance tests and procedures. Estimates of adherence to overall surveillance ranged from 12 to 87 % [2, 18, 21, 24, 29, 36, 43] , with a mean of 12.9 surveillance tests/procedures received by CRC survivors over a 3-year period [21] . Between 17 and 60 % of CRC survivors received surveillance testing below recommended levels, and 18-28 % received testing above recommended levels [24, 33, 36] . Cluster analysis of CRC survivors in France identified three groups of patients with similar surveillance patterns described as "minimal" (47 %), "moderate" (24 %), and "intensive" (29 %) surveillance [17] .
Correlates of adherence
Correlates of CRC surveillance focused largely on nonmodifiable (e.g., sociodemographic and disease/treatment) factors (Table 2 ). Studies generally indicated that CRC survivors who were older, non-White, with more comorbidities and preoperative complications were less likely to receive CRC surveillance [2, 16-18, 21-26, 28, 30, 31, 33, 34, 37, 38, 40-43, 46] . In contrast, CRC survivors who were insured, of higher-income residential zip codes, with colonic site of disease, who underwent preoperative colonoscopy, received adjuvant chemotherapy, or had physician visits/contact (e.g., oncologist, PCP) were generally more likely to receive CRC surveillance [2, 15, 17, 21-23, 26, 28, 30, 31, 37, 38, 41, 43, 45, 46] . Significant variation in receipt of CRC surveillance was also observed across specific U.S. SEER registries [21, 22, 24] and healthcare sites [40, 41] .
The association of gender, marital status, education, household income, geographic location (i.e., urban versus rural), stage at diagnosis, tumor differentiation, receipt of radiation, receipt of surgical resection with reanastomosis, and length of time since diagnosis on receipt of surveillance yielded inconsistent results across studies [2, 15-18, 21-26, 28, 30, 31, 33, 34, 37, 38, 40-43, 46] . A number of studies reported no significant association of neighborhood poverty level, concentration of specialists in the county, tumor location (i.e., proximal versus distal), receipt of adequate (≥12) lymph node evaluation, receipt of polypectomy prior to CRC diagnosis, receipt of emergency surgery, or receipt of follow-up care instructions on receipt of CRC surveillance [16, 21, 28, 34, 37, 43, 47] .
Completeness of reporting on selected characteristics of internal and external validity
Completeness of reporting was variable on six aspects of internal and external validity (Table 3) . Twelve [2, 16, 24-27, 29, 34, 39, 40, 42, 44] of the 34 studies did not provide data regarding the number of potentially eligible participants. Twenty-three studies [15-23, 30-33, 35-39, 41, 43, 45-47] explicitly reported how sample size was determined; for 11 [2, 24-29, 34, 40, 42, 44] data were inferred (e.g., authors reported that sample was determined from a given administrative database) but not explicitly reported. Only 4 studies [15, 31, 37, 38] [2, 16-18, 20-30, 32-36, 39-43, 45-47] made only implicit reference to potential confounders (e.g., adjusted analyses without specific rationale or justification for doing so), and 2 studies [19, 44] did not address confounders. Twenty-nine [2, 15-22, 26, 27, 29-35, 37-47] of the 34 studies provided unadjusted estimates, and all but 7 [16, 19, 20, 32, 35, 39, 44] provided both unadjusted and adjusted estimates. Five studies [23-25, 28, 36] provided only adjusted estimates. Related to generalizability, only 14 [16, 18, 20-22, 27, 34-36, 40, 42, 45-47] of the 34 studies explicitly discussed external validity, while 12 [17, 19, 24-26, 28, 32, 33, 38, 41, 43, 44] made only implicit reference to the issue.
explicitly addressed
Discussion
This systematic review of post-treatment surveillance among CRC survivors demonstrates that deviation from surveillance recommendations includes both under-and overuse. Across all study populations, receipt of colonoscopy among CRC survivors was suboptimal and was not markedly better than recent estimates of colonoscopy (47.5 %) in average-risk populations [53] . Such low prevalence of adherence to surveillance recommendations among CRC survivors is concerning as it compromises the usefulness of post-treatment surveillance for early detection of recurrent or second cancers. o Reflects treatment centers where both diagnosis and treatment occurred at reporting facility (vs. diagnosed elsewhere and treated at reporting facility) or treatment centers who are members of a university health consortium (vs. not a member) p ≤ three studies report no effect q > three studies report no effect
Our review also found overuse of recommended surveillance tests and procedures. Such findings align with recent work by Potosky and colleagues [54] which found that both U.S. oncologists and primary care providers endorse more surveillance tests and at more frequent intervals than recommended by current guidelines. Because younger age and regional stage disease have been associated with overuse of surveillance, these findings may indicate risk stratification on the part of physicians to more aggressively monitor survivors at greater risk for recurrence [24] . However, it has also been posited that physicians may feel pressured to order unnecessary surveillance tests and/or procedures in order to reassure anxious patients [14] . Regardless of the reasons, it is important to emphasize that overuse is just as problematic as suboptimal use. Surveillance is costly and has potential adverse effects (e.g., perforation, false positive [19] Y Y yes, explicitly reported by study authors; I implied by raters but not explicitly reported by study authors; N no, unreported by study authors; STROBE Strengthening the Reporting of Observational Studies in Epidemiology findings); thus, its use should follow established guidelines [9] [10] [11] [12] [13] . Studies of factors associated with adherence to surveillance have focused almost exclusively on patient-level sociodemographic and disease/treatment factors associated with receipt of surveillance. While these findings are useful for identifying groups that need to be prioritized for surveillance (e.g., those lacking reliable access to healthcare), they do not identify modifiable patient factors or other contributing factors beyond the patient (e.g., provider, healthcare system) that may impact adherence to recommended guidelines. This lack of information stands in contrast to the literature on factors associated with CRC screening in average-risk populations. A number of psychosocial variables, including preventive health orientation, knowledge of cancer risk factors, perceived benefits and barriers to screening, self-efficacy, fear or worry about CRC, physician recommendation, and intention, have been consistently associated with CRC screening [55] . Results of a single study to date which examined modifiable psychosocial (i.e., health belief model) factors associated with surveillance among CRC survivors found that only greater perceived likelihood of CRC recurrence was associated with intention to have a colonoscopy; however, completion of the procedure was not examined [56] . Because of the disease experience, it may be that the factors associated with surveillance differ from those associated with screening. Additional research is needed to identify modifiable factors associated with both under-and overutilization of surveillance that can be targeted in future evidence-based interventions with CRC survivors.
A multilevel perspective may represent one useful way of conceptualizing, and ultimately intervening, with the problem of suboptimal and overuse of recommended surveillance tests and procedures among CRC survivors. This perspective recognizes that there are a number of contextual influences (i.e., individual patient, family and social supports, provider/team, local community environment, and state and national health policy) that impact individual behavior throughout the cancer care continuum, from risk assessment through diagnosis and treatment to posttreatment survivorship [57] , as highlighted in a special issue of JNCI monographs [58] . To date, only a few multilevel intervention trials have been conducted targeting health outcomes such as smoking cessation [59] and cardiovascular health [60] . To our knowledge, no interventions have targeted adherence to recommended surveillance among CRC survivors.
At the patient level, CRC survivors may benefit from selfmanagement strategies such as problem solving, decision making, resource utilization, forming partnerships with healthcare providers, and taking action [61] . Support for the utility of self-management interventions in improving cancer survivorship outcomes (e.g., distress, energy, physical activity) has recently been examined among breast cancer survivors [62] [63] [64] . At the provider level, improved communication between oncologists and primary care providers is critical [65, 66] . Survivorship care plans can help facilitate this transition by clearly identifying which provider is responsible for each aspect of follow-up care, thereby reducing the potential for role ambiguity [65] . Results from the few randomized trials to date suggest that primary care providers who received a brief survivorship care plan to inform their care of breast and CRC survivors achieved identical outcomes (e.g., time to detection of recurrence, rate of recurrence-related serious events) as cancer specialists [67] [68] [69] . Primary care providers also appear willing to assume exclusive care of CRC survivors, with appropriate supports (e.g., patient-specific letters from the specialist, printed guidelines, expedited referral sources and access to investigations for suspected recurrence) [70] . Finally, at a healthcare systems level, a better understanding of survivors' healthcare environments and national healthcare policies is critical, particularly given the observed trend toward greater receipt of surveillance among non-U.S. populations, such as Canada, where universal health care is the norm [19, 20, 31, 43, 44] . Careful examination of the referral patterns for and financing of surveillance tests and procedures is important in optimizing the CRC surveillance process.
There are several limitations of this review. Many of the studies utilized the same or overlapping populations from large publicly available databases (e.g., SEER-Medicare). There were also significant differences in how studies operationally defined adherence to surveillance, and some definitions were easier to adhere to than others (e.g., office visits and physical exams versus colonoscopy and CEA testing). As noted by others [5, 14] , this wide variation in surveillance programs has made it difficult to identify the most effective test/procedure (or combination thereof) or the optimal schedule for follow-up, a limitation that warrants additional investigation. The wideranging estimates of surveillance found in this review precluded the use of meta-analysis to aggregate effect sizes of adherence to surveillance. Likewise, because of the limited number of correlates examined and the inconsistent patterns of association, it was not feasible to provide summary estimates.
Despite these limitations, our review provides a comprehensive examination of surveillance practices among heterogeneous groups of CRC survivors from clinic settings and administrative databases (i.e., SEER-Medicare) which include only persons 65 years and older. With few exceptions, only the non-U.S. studies used population-based cancer registries; the use of such registries would represent a useful direction for future research in the USA. Assessment of the completeness of reporting on selected aspects of internal and external validity revealed that relatively little attention was paid to issues of potential confounders and generalizability. This lack of attention in the conduct and reporting of these studies makes it difficult to assess potential threats to internal and external validity [71] . Moving forward, investigations into the prevalence of adherence to posttreatment surveillance among CRC survivors should more clearly examine and report aspects of both internal and external validity. Given that the studies summarized in our review focused predominantly on non-modifiable factors associated with CRC surveillance, there is a need to conduct studies that assess modifiable determinants of surveillance at the patient, provider, and healthcare system levels. Although the feasibility of conducting studies that do not rely on administrative data is admittedly much more challenging, it is only once modifiable determinants have been identified that interventions to increase adherence to recommended surveillance guidelines among CRC survivors can be developed and evaluated. In addition to targeting patient-level modifiable determinants, such interventions should incorporate a multilevel perspective in order to directly and indirectly target a range of modifiable factors that influence both short-(i.e., receipt of surveillance) and longterm (i.e., survival) outcomes of interest.
